Your browser doesn't support javascript.
loading
Efficacy and Safety of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults with Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled Study.
Fleischhacker, W Wolfgang; Hobart, Mary; Ouyang, John; Forbes, Andy; Pfister, Stephanie; McQuade, Robert D; Carson, William H; Sanchez, Raymond; Nyilas, Margareta; Weiller, Emmanuelle.
Afiliação
  • Fleischhacker WW; Department of Psychiatry, Psychotherapy and Psychosomatics, Medical University Innsbruck, Innsbruck, Austria; Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, NJ, USA; H. Lundbeck A/S, Valby, Denmark.
  • Hobart M; Department of Psychiatry, Psychotherapy and Psychosomatics, Medical University Innsbruck, Innsbruck, Austria; Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, NJ, USA; H. Lundbeck A/S, Valby, Denmark.
  • Ouyang J; Department of Psychiatry, Psychotherapy and Psychosomatics, Medical University Innsbruck, Innsbruck, Austria; Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, NJ, USA; H. Lundbeck A/S, Valby, Denmark.
  • Forbes A; Department of Psychiatry, Psychotherapy and Psychosomatics, Medical University Innsbruck, Innsbruck, Austria; Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, NJ, USA; H. Lundbeck A/S, Valby, Denmark.
  • Pfister S; Department of Psychiatry, Psychotherapy and Psychosomatics, Medical University Innsbruck, Innsbruck, Austria; Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, NJ, USA; H. Lundbeck A/S, Valby, Denmark.
  • McQuade RD; Department of Psychiatry, Psychotherapy and Psychosomatics, Medical University Innsbruck, Innsbruck, Austria; Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, NJ, USA; H. Lundbeck A/S, Valby, Denmark.
  • Carson WH; Department of Psychiatry, Psychotherapy and Psychosomatics, Medical University Innsbruck, Innsbruck, Austria; Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, NJ, USA; H. Lundbeck A/S, Valby, Denmark.
  • Sanchez R; Department of Psychiatry, Psychotherapy and Psychosomatics, Medical University Innsbruck, Innsbruck, Austria; Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, NJ, USA; H. Lundbeck A/S, Valby, Denmark.
  • Nyilas M; Department of Psychiatry, Psychotherapy and Psychosomatics, Medical University Innsbruck, Innsbruck, Austria; Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, NJ, USA; H. Lundbeck A/S, Valby, Denmark.
  • Weiller E; Department of Psychiatry, Psychotherapy and Psychosomatics, Medical University Innsbruck, Innsbruck, Austria; Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, NJ, USA; H. Lundbeck A/S, Valby, Denmark.
Int J Neuropsychopharmacol ; 20(1): 11-21, 2017 01 01.
Article em En | MEDLINE | ID: mdl-27566723
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Esquizofrenia / Tiofenos / Antipsicóticos / Quinolonas Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Esquizofrenia / Tiofenos / Antipsicóticos / Quinolonas Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article